Chapter 2 30 Tables Table 1. Baseline characteristics Characteristic Total n=1,431 VKA group n=943 DOAC group n=488 p-value Age (years), mean ± SD 62.4 ± 11.7 62.1 ± 11.6 62.8 ± 12.0 0.32 Male gender 1032 (72.1) 669 (70.9) 363 (74.4) 0.17 BMI, mean ± SD 28.3 ± 5.4 28.3 ± 5.5 28.3 ± 5.1 0.98 TEE 18 (1.3) 13 (1.4) 5 (1.0) 0.80 Medical history Prior TIA 111 (7.8) 71 (7.5) 40 (8.2) 0.65 Prior stroke 106 (7.4) 72 (7.6) 34 (7.0) 0.65 Prior intracranial bleeding 17 (1.2) 15 (1.6) 2 (0.4) 0.069 Prior extracranial bleeding 64 (4.5) 48 (5.1) 16 (3.3) 0.14 Arterial hypertension 612 (42.8) 402 (42.6) 210 (43.0) 0.88 Renal insufficiency* 342 (23.9) 266 (28.2) 76 (15.6) <0.001 Congestive heart failure 333 (23.3) 250 (26.5) 83 (17.0) <0.001 Coronary artery disease 323 (22.6) 239 (25.3) 84 (17.2) <0.001 LVEF ≤40% 304 (21.3) 227 (24.1) 77 (15.8) <0.001 Diabetes mellitus 209 (14.6) 151 (16.0) 58 (11.9) 0.036 Vascular disease 175 (12.2) 119 (12.6) 56 (11.5) 0.53 Congenital heart disease 114 (8.0) 90 (9.5) 24 (4.9) 0.002 Type of atrial tachyarrhythmia Atrial fibrillation 1094 (77.2) 724 (77.7) 370 (76.3) 0.55 Atrial flutter 262 (18.5) 163 (17.5) 99 (20.4) 0.18 Atrial tachycardia 61 (4.3) 45 (4.8) 16 (3.3) 0.22 Scores ASA ≥3 774 (56.3) 543 (59.2) 231 (50.4) 0.002 CHA2DS2-VASc, mean ± SD 2.3 ± 1.6 2.4 ± 1.7 2.2 ± 1.6 <0.001 CHA2DS2-VASc ≥2 935 (65.3) 625 (66.3) 310 (63.5) 0.30 HAS-BLED, mean ± SD 1.3 ± 1.1 1.4 ± 1.1 1.1 ± 1.0 <0.001 HAS-BLED ≥3 176 (12.3) 132 (14.0) 44 (9.0) 0.007 Antiplatelet therapy Acetylsalicylic acid 105 (7.3) 81 (8.6) 24 (4.9) 0.12 Clopidogrel 53 (3.7) 35 (3.7) 18 (3.7) 0.98 Persantin 2 (0.1) 2 (0.2) - 0.55 Ticagrelor 1 (0.1) 1 (0.1) - 1.00 Triple therapy 14 (1.0) 10 (1.1) 4 (0.8) 0.78 Antiarrhythmic therapy Amiodaron 356 (24.9) 271 (28.7) 85 (17.4) <0.001 Sotalol 335 (23.4) 208 (22.1) 127 (26.0) 0.093 Digoxin 286 (20.0) 210 (22.3) 76 (15.6) 0.003 Flecainide 95 (6.6) 53 (5.6) 42 (8.6) 0.031 Verapamil 30 (2.1) 24 (2.5) 6 (1.2) 0.10 Diltiazem 15 (1.0) 9 (1.0) 6 (1.2) 0.63 Propafenone 3 (0.2) 3 (0.3) - 0.56 All data depicted as n (%) unless stated otherwise. * eGFR <60 ml/min/m2. Abbreviations: ASA= American Society of Anaesthesiologists physical status classification system, DOAC = direct-acting oral anticoagulation; LVEF= left ventricular ejection fraction, TEE = transesophageal echocardiogram; VKA= vitamin K antagonist
RkJQdWJsaXNoZXIy MTk4NDMw